GlassScriptPhysician profile
Jason L Buckner
NPI 1750675518
$4,833.69
in general payments reported to CMS, 2019-2025
24 companies · $2,045 in 2025
The $2,045 reported for 2025 was more than what 76% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $49.14 · 2021: $539 · 2022: $712 · 2023: $585 · 2024: $680 · 2025: $2,045.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,298 · Education: $11.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,297.51 |
| Education | $11.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $740.80 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascendis Pharma Endocrinology INC | $605.04 | 2022-2025 | Skytrofa |
| Abbott Laboratories | $456.58 | 2021-2023 | Freestyle Libre 3 |
| Mannkind Corporation | $345.80 | 2021-2025 | |
| Insulet Corporation | $332.05 | 2019-2024 | Omnipod |
| Neurocrine Biosciences, INC. | $266.73 | 2025 | |
| Soleno Therapeutics, INC. | $248.57 | 2025 | Vykat Xr |
| Sanofi-Aventis U.S. LLC | $240.49 | 2023-2024 | |
| Medtronic, INC. | $169.98 | 2025 | Minimed 780g |
| Tolmar Pharmaceuticals, INC. | $169.24 | 2021-2022 | |
| Beta Bionics, INC. | $163.32 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Eton Pharmaceuticals, INC. | $149.89 | 2025 | Increlex, Khindivi, Alkindi |
| Sequel Med Tech, LLC | $139.13 | 2025 | Twiist |
| Pfizer INC. | $138.28 | 2019-2025 | |
| Endo USA, INC. | $133.99 | 2025 | Supprelin |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $122.09 | 2023 | Gvoke Hypopen |
| Azurity Pharmaceuticals, INC. | $116.10 | 2025 | Triptodur |
| Dexcom, INC. | $115.26 | 2021 | |
| Abbvie INC. | $70.32 | 2019-2020 | |
| Novo Nordisk INC | $57.09 | 2019-2020 | |
| Medtronic Minimed, INC. | $16.09 | 2019 | |
| Endo Pharmaceuticals INC. | $13.93 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.76 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $10.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Buckner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.